PYC Therapeutics (ASX:PYC) has announced that the improvements in vision previously reported in patients with Retinitis Pigmentosa type 11 who received a single dose of VP-0014 have been repeated in patients who have received multiple doses of the drug candidate.
The company said that in two out of three patients in this cohort, the treated eye outperformed the untreated eye and showed improvement from baseline across all three endpoints. In the third patient, the treated eye outperformed the untreated eye and showed improvement from baseline across two endpoints, which was equal to the untreated eye in the third endpoint.
The company said there have been no treatment-emergent serious adverse events in any patient who has received VP-001 to date, including those who have now received three doses of the highest dose of VP-001 administered.
PYC will provide a further update on the outcomes of these two multiple-dose studies in the first half of 2025.